There has been a huge increase in cases of TB (tuberculosis) in India over the years, which is quite worrisome. The concern is also about this because India had set a target to make the country TB free by this year (2025), although this goal still seems far away.
Tuberculosis is not just a disease, but a serious public health crisis. Every year millions of people are victims of this infection and a large part of these comes from the poor and weaker sections. The biggest reason for concern about this disease is multi -drug resistant TB (MDR), which does not affect normal medicines. It can be understood that the disease has secured itself against medicines. Since medicines do not affect them, not only the treatment of patients becomes difficult, but the risk of the disease becoming severe and fatal also increases significantly.
MDR TB infection can easily spread from one person to another through air. This means that if it is not stopped in time, then a large number of people can become infected. To prevent this, doctors insist on timely examination, complete treatment, improvement in the patient’s nutritional condition, infection control and awareness campaign in crowded areas.
Drug resistant TB discovered new treatment
Now Indian scientists have discovered neutrassutical medical practice to weaken multi -drug resistant TB, which can help in the patient’s fight against TB by strengthening the patient’s immunity. This medical system is named ATLS-PA 2021, which includes two molecules such as L-Serin and Pameityal CO-A. Researchers from some other institutions along with the Indian Council of Medical Research (ICMR) have made this discovery.
Learn about neutrassutical
Neutrassuticals are products that bring nutrition and medicinal properties together. They not only help in fighting the disease but also increase the immunity of the body. ATLS-PA 2021 is a TB specific product of this category that strengthens body immune response against TB.
Researchers say that problems like prolonged treatment, expensive medicines and high mortality are common in MDR TB cases, so ATLS-PA 2021 can emerge as a low cost, low side effect and more effective option.
This treatment has been discovered especially to increase the effectiveness of traditional anti-TB drugs in MDR TB patients. Experts say, it not only kills the bacteria present in the lungs, but also cures a condition like hypoxia by generating nitric oxide which is common in severe TB cases.
What do experts say?
Deputy Director of Amity Center for Translation Research Prof. Hridayesh Prakash reported that in the treatment of TB, this therapy makes the resistant microbacia resistant to drugs again sensitive to traditional drugs. That is, the medicines which were not affecting before, can be effective again with the help of this medical practice. He told that India has also patented this new discovery.
It is India’s first ICMR approved neutrality, focused on MDR TB. He informed that this innovation will be helpful in fulfilling the targets of TB Free Mission-2025.
Escater pulmonary TB cases also increase
Health experts said that a large number of patients are being diagnosed which have no symptoms of TB infection. When their immunity starts to weaken, its clear signs begin to appear. Usually, cough, mucus for more than 15 days is considered to be symptoms of TB, but without cough- mucus can also cause this disease.
TB of more than 1,000 patients has been examined last year at the Government Institute of Medical Sciences (Jims) in Greater Noida. Out of this, 50 percent of the patients are coming up with Escater Pulmonary TB. Such patients are coming out without cough and cargo.
,
Note: This article has been prepared on the basis of information collected from medical reports.
Disclaimer: It does not claim any kind of information and information provided in this article. Consult your doctor for more information about the related disease mentioned in the above article.